Abstract：Objective To investigate the clinical effect of Sulodexide in the treatment for diabetic nephropathy (DN) patients. Methods A total of 200 patients with DN from January 2011 to January 2018 in Cangzhou Central Hospital, Hebei Province were enrolled in this study. They were divided into combined group and control group by random number table method, with 100 patients in each group. The control group was given basal therapy as hypoglycemic and microcirculation treatment. The combined group was treated with Sulodexide on the basis of the treatment in the control group. The fasting blood-glucose (FPG), blood glucose 2 h after meal (2 h PG), 24 h urinary albumin excretion rate (24 h UAER), serum creatinine (Scr), serum malonaldehyde (MDA), superoxide dismutase (SOD), the number of urinary podocytes, blood and urine monocyte chemoattractant protein 1(MCP-1) were compared before and after treatment. Results After treatment, 24 h UAER, Scr, MDA and urinary podocytes in both groups were significantly lower than those before treatment (P ＜ 0.05), the SOD of the two groups were significantly higher than those before treatment (P ＜ 0.05). After treatment, 24 h UAER, Scr, MDA and urinary podocytes in the combined group were lower than those in the control group (P ＜ 0.05), and SOD was higher than that of the control group (P ＜ 0.05). After treatment, blood and urine MCP-1 of the two groups were significantly lower than those before treatment (P ＜ 0.05), and the blood and urine MCP-1 in the combined group were lower than those in the control group (P ＜ 0.05). Conclusion Sulodexide in the treatment of DN can significantly reduce oxidative stress, blood and urine MCP-1 levels, urinary podocyte levels, and improve renal function.
2019, Vol. 16 
京公网安备 11010502046598号